New Brand, Same MS Drug: Novartis Launches Extavia In Europe
This article was originally published in The Pink Sheet Daily
Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).
You may also be interested in...
Tysabri’s REMS could prove to be a model for drugs with serious safety signals.
Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis
Sandoz sued FDA in its effort to win approval of Omnitrope (somatropin [rDNA origin]). Now the company is using more mundane regulatory procedures as it works to expand sales of its follow-on human growth hormone